Jove
Visualize
Contact Us

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

7.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K
The Ras Gene02:38

The Ras Gene

7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Nascent Pre-Platelets and B4GALT1 Glycosylation Contribute to 5-FU-induced Bone Marrow Recovery.

Blood advances·2026
Same author

ClinASO: An open-source platform for rapid drug discovery of gapmer antisense oligonucleotides.

Molecular therapy. Nucleic acids·2026
Same author

Targeting RBPMS selectively eliminates FOXO1-mediated stem cell signatures in mouse models of acute myeloid leukemia.

Science translational medicine·2026
Same author

Chidamide synergizes with cisplatin-etoposide to trigger pyroptosis and anti-tumor immunity in diffuse large B-cell lymphoma.

Communications medicine·2026
Same author

Maternal IntS11 primes embryonic totipotency by organizing early zygotic transcription initiation.

Proceedings of the National Academy of Sciences of the United States of America·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 4, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

585

TAF1 plays a critical role in AML1-ETO driven leukemogenesis.

Ye Xu1,2, Na Man1,3, Daniel Karl1,3

  • 1Sylvester Comprehensive Cancer Center, University of Miami, 1120 NW 14th St, Miami, FL, 33136, USA.

Nature Communications
|October 31, 2019
PubMed
Summary

TATA-Box Binding Protein Associated Factor 1 (TAF1) binds to acetylated AML1-ETO (AE), promoting leukemia cell growth. Inhibiting TAF1 halts AE-driven leukemia by inducing cell differentiation and apoptosis.

More Related Videos

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.7K
Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

8.6K

Related Experiment Videos

Last Updated: Jan 4, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

585
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.7K
Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

8.6K

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Regulation

Background:

  • AML1-ETO (AE) is an oncogenic fusion protein driving acute myeloid leukemia (AML) via the t(8;21) translocation.
  • Understanding AE's regulatory mechanisms is crucial for developing targeted AML therapies.

Purpose of the Study:

  • To investigate the role of TATA-Box Binding Protein Associated Factor 1 (TAF1) in AE-expressing AML.
  • To elucidate the functional interaction between TAF1 and AE in leukemogenesis.

Main Methods:

  • Chromatin immunoprecipitation sequencing (ChIP-seq) to identify TAF1 and AE binding sites.
  • Knockdown experiments to assess the impact of TAF1 depletion on AE+ AML cells.
  • Analysis of gene expression changes and cellular phenotypes (proliferation, differentiation, apoptosis).

Main Results:

  • TAF1 directly associates with K43 acetylated AE, influencing its chromatin binding.
  • TAF1 knockdown alters AE's regulatory control over target genes, affecting both activation and repression.
  • TAF1 is essential for leukemic cell self-renewal; its reduction promotes differentiation and apoptosis in AE+ AML cells.

Conclusions:

  • TAF1 plays a critical role in AE-driven leukemogenesis by modulating AE's function and maintaining leukemia cell viability.
  • TAF1 represents a promising therapeutic target for treating AE-positive acute myeloid leukemia.